Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy's first year
That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than makes up for the $295 million that Boston Scientific put down to acquire the technology in mid-2021.
That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than makes up for the $295 million that Boston Scientific put down to acquire the technology in mid-2021.
